Trial Profile
Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- Acronyms IVIg-SFN
- 10 Dec 2023 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 25 Mar 2021 Primary endpoint (Change in Pain Intensity Numerical Rating Scale (PI-NRS)) has not been met.
- 25 Mar 2021 Results published in the Neurology.